All In Biotech

BLA 761369 · Pfizer INC

Hympavzi

Marstacimab-Hncq · Subcutaneous

NovelOrphan

CDER novel approval, Oct 11, 2024: To prevent or reduce bleeding episodes related to hemophilia A or B

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Oct 11, 2024

Approved uses

2

Original approval plus efficacy supplements

Registered trials

10

4 Phase 3, 7 recruiting

FAERS reports

103

55 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: THROMBOEMBOLIC EVENTS • Venous and arterial thromboembolic events were reported in patients treated with HYMPAVZI with thrombotic risk factors [see Warnings and Precautions (5.1) ] . • Monitor patients for signs or symptoms of thromboembolism and interrupt use of HYMPAVZI if these occur and manage as clinically indicated [see Warnings and Precautions (5.1) ] . WARNING: THROMBOEMBOLIC EVENTS See full prescribing information for complete boxed warning. • Venous and arterial thromboembolic events were reported in patients treated with HYMPAVZI with thrombotic risk factors. ( 5.1 ) • Monitor patients for signs or symptoms of thromboembolism and interrupt use of HYMPAVZI if these occur and manage as clinically indicated. ( 5.1 )

What it is approved for

From the label in effect Nov 13, 2026.

HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with: • hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors, or • hemophilia B (congenital factor IX deficiency) with or without factor IX inhibitors. HYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with: • hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors, or • hemophilia B (congenital factor IX deficiency) with or without factor IX inhibitors. ( 1 )

Mechanism: Marstacimab‑hncq is a human monoclonal IgG1 antibody directed against the Kunitz domain 2 (K2) of TFPI to neutralize TFPI activity and enhance coagulation. TFPI is the primary inhibitor of the extrinsic coagulation cascade and negatively regulates thrombin generation within the extrinsic pathway of coagulation by inactivating the protease functions of FXa/FVIIa/TF complex. TFPI binds to and inhibits the factor Xa active site via its second Kunitz inhibitor domain (K2).

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 5, 2026 Supplement 3 · Efficacy · priority review OrphanLetterLabel
  • Oct 11, 2024 Original approval · Type 1 - New Molecular Entity NovelOrphanLetterLabelReview
1 products under this application
  • HYMPAVZI · MARSTACIMAB-HNCQ 300MG · INJECTABLE, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Marstacimab" as an intervention, any sponsor and status, largest first.

All 10 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • haemarthrosis21
  • haemorrhage18
  • drug dose omission by device9
  • device defective7
  • device failure6
  • epistaxis6
  • contusion5
  • arthralgia4
  • device malfunction4
  • drug ineffective4
  • joint swelling4
  • product dose omission issue4

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20245
202534
202664

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 9 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.